Excitement for CytomX

Third Rock Ventures expects the $30 million B round it led last week for CytomX Therapeutics LLC will be enough to support several IND filings.

CytomX plans to develop a form of antibodies that can be activated and controlled, and expects to pursue new targets and improve products against known targets. The hope is the platform will produce protease-activated antibody therapeutics with a greater level of tissue selectivity than conventional antibodies...